This project is a continuation of Project 1B. Over the past decade, this SPORE uncovered a select group of disease-causing gene mutations and conspicuously overexpressed genes. It is now appropriate to select a few of these clues that offer the best promise for rational therapeutic targeting of the molecular differences that distinguish the tumors of individual patients.
The specific aims i nclude the characterization of novel cancer mutations, to develop a """"""""pharmacodiagnostic"""""""" algorithm for genetically classifying, treating and advising individual patients, and to uncover a molecular basis for overexpressed tumor antigens to accompany antigen-specific therapies now being initiated. Our long-term goals are to develop a new clinical management strategy for patients presenting with invasive pancreatic cancer that will advise the patient through genetic counseling, advise the surgeon and oncologist as to promising therapies, and then provide specific tools for monitoring the dosage and efficacy of targeted therapies. We will utilize tissues form Core 2 to translate discoveries made in this project to early patient screening being developed in proposed projects 1A and 3A and for improved genetic counseling of families in project 3A and in Core 3. Lay summary: In order to benefit pancreatic cancer patients, we will require a deeper understanding of the molecular basis of the disease and the most specific drug targets: to allow risk assessment and detection at the earliest stage, to understand the reasons for its naturally aggressive course, and to devise effective therapy through rational and individualized approaches. This project will help us to understand the key differences among patients that will enable us to select the proper therapies and provide the appropriate genetic counseling.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Christmas, Brian J; Rafie, Christine I; Hopkins, Alexander C et al. (2018) Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. Cancer Immunol Res 6:1561-1577
Blair, Alex B; Murphy, Adrian (2018) Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future. Curr Probl Cancer 42:49-58
Raman, Aadhithya; Lennon, Anne Marie (2018) Cyst Fluid Biomarkers - Diagnosis and Prediction of Malignancy for Cystic Lesions of the Pancreas. Visc Med 34:178-181
Noë, Michaël; Pea, Antonio; Luchini, Claudio et al. (2018) Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1. Mod Pathol 31:1532-1538
Cohen, Joshua D; Li, Lu; Wang, Yuxuan et al. (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359:926-930
Shumar, Stephanie A; Kerr, Evan W; Geldenhuys, Werner J et al. (2018) Nudt19 is a renal CoA diphosphohydrolase with biochemical and regulatory properties that are distinct from the hepatic Nudt7 isoform. J Biol Chem 293:4134-4148
Li, Yuguo; Qiao, Yuan; Chen, Hanwei et al. (2018) Characterization of tumor vascular permeability using natural dextrans and CEST MRI. Magn Reson Med 79:1001-1009
Saung, May Tun; Muth, Stephen; Ding, Ding et al. (2018) Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. J Immunother Cancer 6:118
Canto, Marcia Irene; Almario, Jose Alejandro; Schulick, Richard D et al. (2018) Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology 155:740-751.e2
Makohon-Moore, Alvin P; Matsukuma, Karen; Zhang, Ming et al. (2018) Precancerous neoplastic cells can move through the pancreatic ductal system. Nature 561:201-205

Showing the most recent 10 out of 883 publications